New therapies are needed for patients with Hodgkin or non-Hodgkin lymphomas that are
resistant to standard therapies. Indeed, unresponsiveness to standard chemotherapy and …

Radiation therapy (RT) is the most effective single modality for local control of non-Hodgkin
lymphoma (NHL) and is an important component of therapy for many patients. Many of the …

Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most
common subtypes of B-cell non-Hodgkin's lymphomas in adults. Histologic transformation of …

Patients with relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL) who
achieve complete response (CR) before autologous stem cell transplantation (ASCT) …

1Department of Haematology, Queen Elizabeth Hospital, Birmingham, 2Department of
Clinical Oncology, Christie Hospital, Manchester, 3PET Imaging Centre, King's College …

Diffuse large B‐cell lymphoma (DLBCL) is the most commonly occurring form of non‐
Hodgkin lymphoma in the western world. Until the mid 1990s the incidence of DLBCL …

Second-line chemotherapy followed by high-dose therapy (HDT) with autologous stem cell
transplantation (ASCT) cures less than half of the patients with relapsed or refractory diffuse …

Purpose This clinical trial evaluated standard-dose radioimmunotherapy with a
chemotherapy-based transplantation regimen followed by autologous hematopoietic cell …

The poor prognosis for patients with diffuse large B cell lymphoma (DLBCL) who relapse
within 1 year of initial diagnosis after first-line rituximab-based chemo-immunotherapy has …

Importance Axicabtagene ciloleucel, a chimeric antigen receptor T-cell therapy, represents a
new and potentially curative treatment option for B-cell lymphoma. It is expected to have …